Would you consider adding atezolizumab to chemotherapy for metastatic esophageal small cell cancer?

I would consider adding atezolizumab (and indeed I have in the past). Of course, this would be based on the SCLC literature from the IMpower133 and CASPIAN trials where atezolizumab and durvalumab respectively improved outcomes when combined with platinum/etoposide chemotherapy.

But there is a cavea...